American Century Companies Inc. Sells 94,950 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

American Century Companies Inc. lowered its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 35.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 170,185 shares of the biopharmaceutical company’s stock after selling 94,950 shares during the period. American Century Companies Inc. owned approximately 0.14% of Catalyst Pharmaceuticals worth $2,636,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. UBS Group AG increased its position in Catalyst Pharmaceuticals by 37.7% during the fourth quarter. UBS Group AG now owns 469,316 shares of the biopharmaceutical company’s stock valued at $7,889,000 after acquiring an additional 128,595 shares during the last quarter. Franklin Resources Inc. raised its position in Catalyst Pharmaceuticals by 21.9% in the 4th quarter. Franklin Resources Inc. now owns 185,923 shares of the biopharmaceutical company’s stock worth $3,125,000 after purchasing an additional 33,397 shares during the period. US Bancorp DE lifted its stake in Catalyst Pharmaceuticals by 63.9% in the fourth quarter. US Bancorp DE now owns 65,175 shares of the biopharmaceutical company’s stock worth $1,096,000 after purchasing an additional 25,418 shares during the last quarter. Alberta Investment Management Corp boosted its position in shares of Catalyst Pharmaceuticals by 50.0% during the fourth quarter. Alberta Investment Management Corp now owns 101,700 shares of the biopharmaceutical company’s stock valued at $1,710,000 after buying an additional 33,900 shares during the period. Finally, Opaleye Management Inc. grew its stake in shares of Catalyst Pharmaceuticals by 4.3% during the fourth quarter. Opaleye Management Inc. now owns 1,257,200 shares of the biopharmaceutical company’s stock valued at $21,436,000 after buying an additional 52,200 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $19.56 on Friday. Catalyst Pharmaceuticals, Inc. has a one year low of $11.55 and a one year high of $21.67. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 36.22, a price-to-earnings-growth ratio of 3.27 and a beta of 0.75. The company’s 50-day simple moving average is $19.22 and its two-hundred day simple moving average is $16.95.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. The company had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. Equities analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CPRX. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Oppenheimer reissued an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright raised their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $29.50.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director David S. Tierney sold 15,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Carmen Jeffrey Del sold 36,058 shares of Catalyst Pharmaceuticals stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the transaction, the insider now directly owns 12,369 shares in the company, valued at $227,836.98. The disclosure for this sale can be found here. In the last three months, insiders sold 201,058 shares of company stock valued at $4,018,188. Corporate insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.